Consensus CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.59 ^USD	-0.62%		-4.79%	+2.58%

04-22	JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	MT
04-08	CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	CI

Evolution of the average Target Price on CytomX Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e2850a256437e30.TnozRHkLRbtIhiHMZcMW_CG5I0m4kZoBaW_20AqdCP0.KCV5CUt-D-kx5EOlKvt9lBT_ZQWA1K5YHyae4kD7b597OUoOJlEG0i6yTg~7d4c4a450e4480fff542a92e9c05f026

Analyst Recommendations on CytomX Therapeutics, Inc.

JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	04-22	MT
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	03-12	MT
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	11-09	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.19 From $3.15, Keeps Market Perform Rating	09/08/23	MT
Mizuho Securities Adjusts CytomX Therapeutics Price Target to $2 From $4, Maintains Neutral Rating	28/03/23	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.20 From $2.60, Maintains Market Perform Rating	06/01/23	MT
BMO Capital Downgrades CytomX Therapeutics to Market Perform From Outperform, Adjusts Price Target to $2.60 From $3	14/11/22	MT
JPMorgan Downgrades CytomX Therapeutics to Underweight From Overweight	10/11/22	MT
Cowen Downgrades CytomX Therapeutics to Market Perform From Outperform	11/07/22	MT
HC Wainwright Downgrades CytomX Therapeutics to Neutral From Buy	11/07/22	MT
Jefferies Downgrades CytomX Therapeutics to Hold From Buy, Lowers Price Target to $2 From $12	07/07/22	MT
Piper Sandler Downgrades CytomX Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.50 From $10	07/07/22	MT
BTIG Lowers CytomX Therapeutics' Price Target to $8 From $16, Buy Rating Kept	07/07/22	MT
BMO Capital Lowers CytomX Therapeutics' Price Target to $3 From $9, Outperform Rating Maintained	07/07/22	MT
Barclays Adjusts CytomX Therapeutics' Price Target to $3.50 From $7, Keeps Overweight Rating	07/07/22	MT
Wedbush Cuts CytomX Therapeutics to Neutral From Outperform, Price Target to $2 From $6, Citing Praluzatamab Ravtansine Update, 'Tough Financing Environment'	07/07/22	MT
Piper Sandler Cuts CytomX Therapeutics to Neutral From Overweight, Price Target to $1.50 From $10	07/07/22	MT
Mizuho Securities Cuts CytomX Therapeutics to Neutral From Buy, Price Target to $4 From $16	07/07/22	MT
BMO Capital Starts CytomX Therapeutics at Outperform With $9 Price Target	24/06/22	MT
Piper Sandler Adjusts Price Target on CytomX Therapeutics to $10 From $16, Reiterates Overweight Rating	31/05/22	MT
Wedbush Adjusts Price Target for CytomX Therapeutics to $6 From $10, Maintains Outperform Rating	10/05/22	MT
Barclays Upgrades CytomX Therapeutics to Overweight from Underweight, Keeps $7 Price Target	18/01/22	MT
HC Wainwright Adjusts CytomX Therapeutics' Price Target to $11 From $12, Keeps Buy Rating	22/12/21	MT
JPMorgan Adjusts Price Target for CytomX Therapeutics to $10 from $12, Maintains Overweight Rating	21/12/21	MT
Jefferies & Co Adjusts CytomX Therapeutics PT to $12 From $14, Maintains Buy Rating	21/12/21	MT